Lauren C. Aguado

Lauren C. Aguado

Auto-generated profile, based on publicly available information

Lauren C. Aguado

Department of Microbiology, Icahn School of Medicine at Mount Sinai, New York, NY 10029, USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 June 2021 in Nature
Verified
Journal Article
Open access
PDF file
ZWZijun Wang
Zijun Wang
FMFrauke Mücksch
Frauke Mücksch
DSDennis Schaefer-Babajew
Dennis Schaefer-Babajew
SFShlomo Finkin
Shlomo Finkin
CVCharlotte Viant
Charlotte Viant
MNMichel C. Nussenzweig
Michel C. Nussenzweig
More than one year after its inception, the coronavirus disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) remains difficult to control despite the availability of several working vaccines. Progress in controlling the pandemic is slowed by the emergence of variants that appear to be more transmissible and more resistant to antibodies1,2. Here we report on a cohort of 63 individuals who have recovered from COVID-19 assessed at 1.3, 6.2 and 12 months after SARS-CoV-2 infection, 41% of whom also received mRNA vaccines3,4. In the absence of vaccination, antibody reactivity to the receptor binding domain (RBD) of SARS-CoV-2, neutralizing activity and the number of RBD-specific memory B cells remain relatively stable between 6 and 12 months after infection. Vaccination increases all components of the humoral response and, as expected, results in serum neutralizing activities against variants of concern similar to or greater than the neutralizing activity against the original Wuhan Hu-1 strain achieved by vaccination of naive individuals2,5–8. The mechanism underlying these broad-based responses involves ongoing antibody somatic mutation, memory B cell clonal turnover and development of monoclonal antibodies that are exceptionally resistant to SARS-CoV-2 RBD mutations, including those found in the variants of concern4,9. In addition, B cell clones expressing broad and potent antibodies are selectively retained in the repertoire over time and expand markedly after vaccination. The data suggest that immunity in convalescent individuals will be very long lasting and that convalescent individuals who receive available mRNA vaccines will produce antibodies and memory B cells that should be protective against circulating SARS-CoV-2 variants.

14 August 2013 in Science Translational Medicine
Verified
Journal Article
Closed access
PDF file
MMMatthew Miller
Matthew Miller
TGThomas Gardner
Thomas Gardner
Florian KrammerFlorian Krammer
Florian Krammer
LALauren C. Aguado
Lauren C. Aguado
DTDomenico Tortorella
Domenico Tortorella
PPPeter Palese
Peter Palese
Antigenic variation promotes neutralizing antibodies to both seasonal and pandemic influenza A strains in humans.

28 June 2017 in Nature
Verified
Journal Article
Open access
PDF file
LALauren C. Aguado
Lauren C. Aguado
SSSonja Schmid
Sonja Schmid
JMJared May
Jared May
LSLeah R. Sabin
Leah R. Sabin
MPMaryline Panis
Maryline Panis
BTBenjamin R. Tenoever
Benjamin R. Tenoever
RNase III from all three domains of life elicits RNA-targeting antiviral activity that is independent of, and possibly predates, other known eukaryotic antiviral systems. Benjamin tenOever and colleagues reveal a direct antiviral role for the mammalian RNase III protein Drosher that is unrelated to its role in miRNA metabolism. They propose that it acts as an antiviral clamp that recognizes RNA structures commonly found in positive-stranded RNA viruses and impedes the activity of viral RNA-dependent RNA polymerases. They also show that this activity can be observed in RNase III nucleases from diverse domains of life, suggesting that it may have represented an ancient antiviral system. In contrast to the DNA-based viruses in prokaryotes, the emergence of eukaryotes provided the necessary compartmentalization and membranous environment for RNA viruses to flourish, creating the need for an RNA-targeting antiviral system1,2. Present day eukaryotes employ at least two main defence strategies that emerged as a result of this viral shift, namely antiviral RNA interference and the interferon system2. Here we demonstrate that Drosha and related RNase III ribonucleases from all three domains of life also elicit a unique RNA-targeting antiviral activity. Systemic evolution of ligands by exponential enrichment of this class of proteins illustrates the recognition of unbranched RNA stem loops. Biochemical analyses reveal that, in this context, Drosha functions as an antiviral clamp, conferring steric hindrance on the RNA-dependent RNA polymerases of diverse positive-stranded RNA viruses. We present evidence for cytoplasmic translocation of RNase III nucleases in response to virus in diverse eukaryotes including plants, arthropods, fish, and mammals. These data implicate RNase III recognition of viral RNA as an antiviral defence that is independent of, and possibly predates, other known eukaryotic antiviral systems.

28 April 2014 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
PDF file
JSJillian S. Shapiro
Jillian S. Shapiro
SSSonja Schmid
Sonja Schmid
LALauren C. Aguado
Lauren C. Aguado
LSLeah R. Sabin
Leah R. Sabin
AYAri Yasunaga
Ari Yasunaga
BTBenjamin R. Tenoever
Benjamin R. Tenoever
Significance: Virus infections must be combated at a cellular level. The strategies used to inhibit virus differ dramatically when comparing plants and insects to mammals. Here, we identify an evolutionary conserved antiviral response that is independent of these known defenses. We demonstrate that an RNA nuclease called Drosha is repurposed during virus infection to cleave viral RNA and modulate the cellular environment as a means of inhibiting virus replication.

1 December 2015 in Cell Host & Microbe
Verified
Journal Article
Closed access
LALauren C. Aguado
Lauren C. Aguado
SSSonja Schmid
Sonja Schmid
DSDavid Sachs
David Sachs
JSJaehee V. Shim
Jaehee V. Shim
JLJean K. Lim
Jean K. Lim
BTBenjamin R. Tenoever
Benjamin R. Tenoever

31 May 2018 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
LALauren C Aguado
Lauren C Aguado
BTBenjamin Tenoever
Benjamin Tenoever